We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Athera and Boehringer Ingelheim Enter Into an Option Agreement

News   Jun 21, 2013

 
Athera and Boehringer Ingelheim Enter Into an Option Agreement
 
 
 

RELATED ARTICLES

Post-heart Attack Antibody Levels May Guide Treatment

News

Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity.

READ MORE

Cellular Dumpster-diving Enables Degradation Landscape Exploration

News

A novel technology for profiling protein turnover and degradation offers new insight into diagnosis and understanding the molecular basis of autoimmunity, cancer, neurodegeneration and other disorders.

READ MORE

Aspirin Stops Clots After Knee Surgery

News

Putting patients on aspirin following a knee replacement is a safe, cost-effective alternative to anticoagulants, U-M researchers find.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE